

**Mouse Anti-CD20 (B Cell) [L26]: MC0056, MC0056RTU7**

**Intended Use:** For Research Use Only

**Description:** CD20 is a transmembrane phosphoprotein which functions as a calcium-permeable cation channel involved in B cell activation, proliferation and differentiation. It is expressed on both normal and malignant B cells. The expression of CD20 is observed in all mature B lymphocytes but lost in terminal differentiated plasma cells. CD20 is one of the most important markers for B cell. It labels almost all mature B cell lymphoma, half of lymphoblastic lymphoma/leukemia and Reed-Sternberg cells in Hodgkin's disease. It has also been used to monitor down regulation of CD20 in patient treated with Rituximab for B cell lymphoma.

**Specifications**

Clone: L26  
 Source: Mouse  
 Isotype: IgG2a/k  
 Reactivity: Human  
 Localization: Membrane, cytoplasm  
 Formulation: Antibody in 10 mM PBS, 1% BSA, 0.09% sodium azide (NaN<sub>3</sub>).  
 Storage: Store at 2°- 8°C  
 Applications: IHC, Flow Cyt., ICC/IF, IP, WB  
 Package:

Description	Catalog No.	Size
CD20 (B Cell) Concentrated	MC0056	1 ml
CD20 (B Cell) Prediluted	MC0056RTU7	7 ml

**IHC Procedure\***

Positive Control Tissue: Tonsil, lymph node, B cell lymphoma  
 Concentrated Dilution: 50-200  
 Pretreatment: EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C  
 Incubation Time and Temp: 30-60 minutes @ RT  
 Detection: Refer to the detection system manual

\* Result should be confirmed by an established diagnostic procedure.



FFPE human tonsil stained with anti-CD20 using DAB

**References:**

1. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. Ricciardelli I, et al. Blood 124:2514-22, 2014.
2. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Leung-Hagesteijn C, et al. Cancer Cell 24:289-304, 2013.
3. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Dalle S, et al. Mol Cancer Ther 10:178-85, 2011.
4. Endothelial damage in all types of T-lymphocyte-mediated drug-induced eruptions. Verneuil L et al. Arch Dermatol 147:579-84, 2011.

Doc. 100-MC0056  
Rev. A